

NmC, a new antithrombotic candidate

Enemce Pharma S.L.


Madrid, 27 de noviembre de 2013

Enemce Pharma SL

- François Arcand, CEO
- Jordi Naval, COO
- Dr Jesús Llenas,
Pharmacology
- Dr Javier Fábregas,
CMC
- Martin Austin, Business
Development

Mission:
Developing new SSRIs
derivatives as
antiplatelet drugs

SSRIs help prevent MI?



Kimmel, BJCP, 72: 514-517 (2011)

Epidemiology says: **SSRIs reduce 2nd MI risk by**

40%

(20%-30% reduction with Plavix + Aspirin)



Potency:

Citalopram > paroxetine > fluoxetine
> other SSRIs




0,013% incidence of **bleeding** with SSRIS

0,2% with Aspirin

0,32% with Clopidogrel


So, what is NmC

- Citalopram derivative
- Charged, does not cross BBB
- Exclusive License from Tel-Aviv University
- **New Composition of Matter Patents**
 - NmC and other SSRI derivatives
 - Granted: France, Germany, UK, China,
 - Application: USA, India, Spain




N-methyl-citalopram (NmC)

Current antiplatelets




New systemic-only SSRIs

Data on Efficacy




Data on Safety




Bioavailability

- Low oral, to be improved

Where do we see NmC?



Market Opportunity



Antithrombotics 2018
Worldwide, B US\$

Interesting deals

Acquisitions in 2009 - phase I completed



Elinogrel
Antiplatelet

Signature
Phase I

55M €

Milestones
Phase II, III

365M €

Royalties

± 15%



Betrixaban
Anticoagulant

37M €

307M €

± 15%

What have we done so far, and next steps



Current program

1. Improve Oral Bioavailability
2. Animal assays (mice) to establish the antiplatelet efficacy of different dosages of NmC in oral formulations
3. License fees and IP maintenance

Why Invest / Partner / co-Develop?

- New molecule, new MoA
- Strong, clear IP
- Potentially Safe, Efficacious and Oral
- Big Market (Antiplatelets)
- Pharma avidity for new compounds
- Experienced Team
- Directed to license after completed Phase I (End 2017)